美国食品药品管理局(FDA)2011年2月4日批准己酸羟孕酮(商品名,Makena)注射液用于预防已有自发性早产史的妊娠女性不足37周妊娠发生早产的风险。该药物不适用于多胎妊娠的女性,如双胞胎妊娠,或致早产的其他风险因素。FDA通过加 The U.S. Food and Drug Administration (FDA) approved February 4, 2011 that Makena (caproxyprogesterone caproate) (Makena) injection was used to prevent premature birth in 37-week-old pregnant women who had a history of spontaneous preterm birth. The drug is not suitable for women with multiple pregnancies, such as twin pregnancies, or other risk factors for preterm labor. FDA passed